Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MF2 | ISIN: US7574683014 | Ticker-Symbol: 2RH
NASDAQ
06.06.25 | 15:30
1,960 US-Dollar
+3,16 % +0,060
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer18
13.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
05.05.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
28.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer12
17.04.RedHill Biopharma steht vor Compliance-Problemen mit der NASDAQ32
17.04.RedHill Biopharma faces Nasdaq non-compliance issue3
17.04.RedHill Biopharma receives Nasdaq letter over minimum stockholders' equity deficiency2
17.04.RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency126The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected...
► Artikel lesen
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
16.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer2
10.04.RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights660Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: ...
► Artikel lesen
10.04.RedHill Biopharma Ltd. - 20-F, Annual and transition report of foreign private issuers3
08.04.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer10
26.03.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
25.03.RedHill Biopharma Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
18.03.RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation603RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK...
► Artikel lesen
12.03.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer8
25.02.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer17
04.02.RedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer Treatment12
04.02.RedHill Biopharma Ltd.: RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer294The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic...
► Artikel lesen
03.02.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer6
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3